AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLL
Roche and AbbVie’s Venclexta approved in CLL
AbbVie/Roche seek first-line CLL use for Venclexta combo
AbbVie and J&J claim new Imbruvica okay in US
Blockbuster likely to face cheap near-copy for first time.
Roche’s Mabthera faces cut-price competition in EU
AbbVie blood cancer drug tipped to be a blockbuster.
AbbVie’s Venclyxto approved in Europe in CLL
Leukaemia drug likely to get conditional approval.
AbbVie’s CLL drug recommended in Europe